PM: Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2018
AH: Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate
PR: Heidelberg Pharma AG: Interim management statement on the first nine months of 2018
PR: Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
PR: Heidelberg Pharma Presents at Upcoming Conferences and Investor Events
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018
PM: Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences
PM: Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update
PR: Heidelberg Pharma and Magenta Therapeutics Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates
AH: Heidelberg Pharma and Magenta Therapeutics Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates
PR: Heidelberg Pharma Signs License Agreement with The University of Texas MD Anderson Cancer Center
PR: Heidelberg Pharma AG and Advanced Proteome Therapeutics Progress Collaborative Program
